Cellbxhealth PLC DRC (ANPCY)

Currency in USD
0.0670
-0.0018(-2.62%)
Closed·
Showing Cellbxhealth DRC historical data. For real-time data please try another search
Fair Value
Day's Range
0.06700.0680
52 wk Range
0.06662.3900
Key Statistics
Prev. Close
0.067
Open
0.068
Day's Range
0.067-0.068
52 wk Range
0.0666-2.39
Volume
20.48K
Average Volume (3m)
21.69K
1-Year Change
-95.037%
Book Value / Share
0.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANPCY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Cellbxhealth PLC DRC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Cellbxhealth DRC Company Profile

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Compare ANPCY to Peers and Sector

Metrics to compare
ANPCY
Peers
Sector
Relationship
P/E Ratio
−0.8x9.0x−0.6x
PEG Ratio
−0.030.050.00
Price/Book
1.1x1.4x2.6x
Price / LTM Sales
4.8x2.1x3.4x
Upside (Analyst Target)
-211.1%41.1%
Fair Value Upside
Unlock16.0%5.3%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Sep 09, 2025
EPS / Forecast
-0.03 / --
Revenue / Forecast
796.00K / --
EPS Revisions
Last 90 days
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.